Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have ...
Qurient announced the first patient dosed in a Phase 2 study of mocaciclib (Q901) for CDK4/6 inhibitor-resistant HR+ breast ...
In a recent study posted to the bioRxiv* pre-print server, researchers investigated coronavirus disease 2019 (COVID-19)-triggered changes in the levels of cyclins and cyclin-dependent kinases (CDKs) ...
Phase 1a/b Study for Selective Brain-Penetrant CDK2 Inhibitor AL-605 doses patients; Selective Brain-Penetrant CDK4 Inhibitor AL-433 on Track for First-in-Human Study SAN DIEGO, May 29, 2026 ...
Proxygen GmbH has disclosed molecular glue degraders comprising a cullin-ring E3 ligase (CRL) binding moiety acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers. They are ...
AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) has been ...
Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results